Development · 18 Oct 2026
7 publishers have reported this development. Each act of reporting is below, cited.
The Centre has finalized a 30 per cent trade margin cap for 137 non-scheduled anti-cancer drugs.
The Centre approved a cap on the margins of non-scheduled anti-cancer drugs, limiting margins to 30 percent of the Maximum Retail Price.
The Centre informed the Supreme Court that it had decided to cap trade margins at 30 percent for non-scheduled cancer drugs.
The Centre submitted a proposal to limit trade margins on listed anti-cancer drugs to 30 percent of their maximum retail price.
India's NPPA has approved capping trade margins on non-scheduled cancer drugs at 30% of MRP, targeting markups that averaged about 170% and reached 700% in some cases.
Shares of hospital sector companies including Fortis Healthcare, Apollo Hospitals, Manipal Health, and Max Healthcare rose up to 5% on Friday after the government capped trade margins on non-scheduled anti-cancer drugs at 30%.
Hospital stocks rallied after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, potentially cutting prices by 20–70% and saving patients ₹ 2,500 crore annually.
Max Healthcare, Apollo Hospitals, and other hospital shares rose up to 4% on October 9 after the Centre decided to cap trade margins at 30% of the MRP for all non-scheduled anti-cancer drugs.
Hospital stocks including Fortis Healthcare, Dr Agarwal’s, Manipal, Apollo Hospitals and Medanta gained up to 5% on Friday, after the government decided to cap trade margins on non-scheduled anti-cancer drugs at 30%.
The Centre has decided to cap trade margins for all non-scheduled anti-cancer drugs at 30 per cent of the MRP.
The Centre is preparing to cap trade margins on all non-scheduled anti-cancer medicines at 30% of their maximum retail price.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.